V
主页
Understanding & predicting outcomes in CAR T-cell therapy
发布人
打开封面
下载高清视频
观看高清视频
视频下载器
2022 WMIF,The Cell Therapy Landscape,CAR-T to Stem Cells
Simplifying GMP CAR T and CAR NK cell therapy manufacturing processes
Industrialization of Cell Therapy Manufacturing
CAR-T Cell Therapy_ Now and in 2030
Removing analytical bottlenecks in cell therapy
CAR-T Generation for Identity, Purity and Potency Assay Testing
All you need for T cell research
Cell therapy logistics_ Exploring the last 100m
Utilizing the Gibco CTS Rotea System for cell and gene therapy development
Stem Cell Therapie's Potential in the Pandemic Era
2022 WMIF,Cell Therapy and Transplantation for Parkinson'sease
Methods to advance your CAR T & CAR NK cell research
A cGMP Compatible, Non-Viral CAR T Cell Manufacturing Process
GMP Raw Materials for Cell Therapy - What, When, How?
GMP requirements for cell and gene therapy institutions
Meeting Regulatory Requirements for Cell and Gene Therapy Manufacturing
Off-the-shelf NK cell therapy [WEBINAR]
Manufacturing of gene-engineered hematopoietic stem cells
A CRISPR Vision for the Future of Cell Therapy
How cell and gene therapies can transform the treatment of solid tumours
High-Quality Plasmid DNA Manufacturing Strategies for Gene and Cell Therapeutics
Addressing the challenges of cell and gene therapy manufacturing
Automated, closed manufacturing and sorting of PSCs and their derivatives
Understanding the Vaccine Manufacturing Process & Facility Design Consideration
CAR-T细胞治疗优劣及发展方向
Keynote_ Carl June | Therapy Gladstone-UCSF
FT596_ iPSC-derived CAR-NK cells with engineered persistence for B-cell malignan
A Beginner's Guide to Single Cell Sequencing
Dr. Carl June Presenting at Nobel Conference
Blocking ADAM17 as a therapeutic approach to increase human NK cell proliferatio
Michel Sadelain - iPSC Derived CAR-Ts Targeting Cancer with an Engineered- iPSC-
CFDI《细胞质量产品GMP指南》解读
基因治疗药物的CMC开发策略
GMP cell banks as part of a staged, standardized, platform-style cell process
细胞治疗系列CAR-T疗法在实体瘤治疗中的突破和进展
生物大分子与细胞冻融工艺应用
Engineering iPSC-derived Natural Killer Cells
Evaluating expression patterns of multiple inhibitory and stimulatory receptors
EU GMP Annex 1 Update_ Implications for Sterile Products Manufacture
Fate Therapeutics Introduction